The role of MAPK pathway in bone and soft tissue tumors.

AIM Expression of mitogen-activated protein kinase (MAPK) signaling and its role in cell proliferation of the bone malignancies, osteosarcoma (OS) and malignant fibrous histiocytoma (MFH) were investigated. MATERIALS AND METHODS Gene expression and protein levels of RAF1 and MEK1/2 in 6 human sarcoma cell lines and 7 surgically obtained OS specimens were assessed by RT-PCR and immunohistochemistry, respectively. MEK inhibitor, U0126 [1,4-diamino-2,3-dicyano-1,4-bis (2-aminophynyltio) butadiene], was used for cell proliferation assays. RESULTS RAF1 and MEK 1/2 mRNA was detected in all cell lines and OS specimens. RAF1, MEK 1/2 and p-MEK protein was also expressed in the cells, as was MEK1/2 in OS specimens. Treatment with U0126 resulted in dose- and time-dependent inhibition of cell proliferation and suppression of p-ERK expression, opposite to promotion of p-MEK. CONCLUSION U0126 blocks MAPK signaling and decreases cell proliferation in OS and MFH. Thus, selective MAPK inhibitors might be therapeutically advantageous in the treatment of bone and soft tissue sarcomas.

[1]  Tao Ji,et al.  Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway , 2009, Cancer biology & therapy.

[2]  R. Foà,et al.  Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. , 2009, Neoplasia.

[3]  P. Galle,et al.  A systems biology perspective on cholangiocellular carcinoma development: focus on MAPK-signaling and the extracellular environment. , 2009, Journal of hepatology.

[4]  Amy Young,et al.  Ras signaling and therapies. , 2009, Advances in cancer research.

[5]  M. Bissonnette,et al.  Sorafenib inhibits MAPK-mediated proliferation in a Barrett's esophageal adenocarcinoma cell line. , 2008, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[6]  M. Nagino,et al.  MEK inhibitor enhances the inhibitory effect of imatinib on pancreatic cancer cell growth. , 2008, Cancer letters.

[7]  Yan Ding,et al.  Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma , 2008, Molecular Cancer Therapeutics.

[8]  H. Fujioka,et al.  Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo. , 2007, Anticancer research.

[9]  H. Fujioka,et al.  Expression of VEGF and its receptors and angiogenesis in bone and soft tissue tumors. , 2006, Anticancer research.

[10]  M. Hidalgo,et al.  Novel targets in solid tumors: MEK inhibitors. , 2006, Clinical advances in hematology & oncology : H&O.

[11]  H. Basaga,et al.  Protein kinases as drug targets in cancer. , 2006, Current cancer drug targets.

[12]  S. Wilhelm,et al.  Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. , 2006, Seminars in oncology.

[13]  A. J. Mixson,et al.  Small interfering RNA targeting Raf-1 inhibits tumor growth in vitro and in vivo , 2005, Cancer Gene Therapy.

[14]  T. Okumura,et al.  Involvement of MEK-ERK signaling pathway in the inhibition of cell growth by troglitazone in human pancreatic cancer cells. , 2005, Biochemical and biophysical research communications.

[15]  M. Kurosaka,et al.  Establishment and characterization of a KIT‐positive and stem cell factor‐producing cell line, KTHOS, derived from human osteosarcoma , 2005, Pathology international.

[16]  L. Goodglick,et al.  Inhibition of the Raf–MEK1/2–ERK1/2 Signaling Pathway, Bcl-xL Down-Regulation, and Chemosensitization of Non-Hodgkin’s Lymphoma B Cells by Rituximab , 2004, Cancer Research.

[17]  Piero Picci,et al.  Contribution of MEK/MAPK and PI3‐K signaling pathway to the malignant behavior of Ewing's sarcoma cells: Therapeutic prospects , 2004, International journal of cancer.

[18]  C. Bucana,et al.  Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  M. Kurosaka,et al.  Immunohistochemical analysis of platelet-derived growth factor and its receptors in soft tissue malignant fibrous histiocytoma. , 2003, Anticancer Research.

[20]  G. Antoch,et al.  Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT , 2003, Cancer Chemotherapy and Pharmacology.

[21]  D. Ettinger,et al.  The use of chemotherapy in soft-tissue sarcomas. , 2002, The oncologist.

[22]  M. Kurosaka,et al.  Establishment and characterization of cell line TNMY1 derived from human malignant fibrous histiocytoma , 2001, Pathology international.

[23]  Y. Uemura,et al.  Novel cell lines established from a human myxoid malignant fibrous histiocytoma arising in the uterus. , 2001, Cancer genetics and cytogenetics.

[24]  K. Shinomiya,et al.  Establishment and characterization of a cell line from a malignant fibrous histiocytoma of bone developing in a patient with multiple fibrous dysplasia , 2001, Journal of Cancer Research and Clinical Oncology.

[25]  G. Bodoky,et al.  The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma , 2000, Cancer.

[26]  Peter Gierschik,et al.  Growth factor-dependent activation of the Ras-Raf-MEK-MAPK pathway in the human pancreatic carcinoma cell line PANC-1 carrying activated K-ras: implications for cell proliferation and cell migration , 2000, Oncogene.

[27]  S. Wingren,et al.  Human malignant fibrous histiocytomas in vitro: growth characteristics and their association with expression of mRNA for platelet-derived growth factor, transforming growth factor-alpha and their receptors. , 1998, European journal of cancer.

[28]  T Takahashi,et al.  Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. , 1991, Oncogene.